Arima Genomics Announces Distribution Partnership with Active Motif

Under the agreement, Active Motif will receive exclusive rights to distribute Arima's Hi-C kits and research services for research applications.

Active Motif will distribute Arima's full range of 3D genomics research kits and services for non-FFPE samples, including cell lines, blood, and fresh-frozen tissue.

These products support research in epigenetics, gene regulation, human health and disease, and high-quality genome assembly and haplotype phasing, helping advance functional and evolutionary genomics.

Read More:Six Flags Appoints Mark Pauls Chief Operating Officer

The distribution partnership supports Arima's strategy of focusing on its core clinical diagnostics business. The company's proprietary Hi-C sequencing technology analyzes the 3D structure of cancer genomes from routine FFPE tissue samples.

This technology powers Arima's clinical tests, Aventa FusionPlus for solid tumors and Aventa Lymphoma, which help identify important gene fusions and rearrangements that may be missed or only partially detected by traditional testing methods.

“We believe the future of cancer diagnostics lies in understanding more of what the genome has to reveal — bringing together DNA sequence and structure to expose the true drivers of disease,” said Tom Willis, Ph.D., CEO of Arima Genomics. “This agreement allows Arima to focus our resources on advancing that vision through our Aventa clinical diagnostics platform, while ensuring that researchers continue to access these tools through Active Motif’s established commercial infrastructure, complementary product portfolio and deep relationships across the life sciences research community.”

“Arima has built a differentiated technology platform that is changing how clinically meaningful genomic alterations are detected and understood in cancer,” said Malek Faham, M.D., Ph.D., Chief Scientist at Illumina Ventures. “This agreement sharpens the Company’s focus on the clinical opportunity, where it is well positioned to address important limitations of conventional testing and deliver insights that can inform patient care.”

About Arima Genomics

Founded in 2015, Arima Genomics is a cancer diagnostics company that uses 3D genome science and Hi-C sequencing technology to improve cancer testing. Its tests are designed to detect cancer-related genetic changes that traditional testing methods may miss. Through its Aventa brand, the company provides clinical testing for solid tumors and lymphoma from its CLIA-certified laboratory in Orlando, Florida.

About Active Motif

Founded in 1999, Active Motif is a provider of epigenetics, genomics and multiomics research solutions. The company offers products, services, and scientific expertise that help researchers study gene regulation, chromatin biology and disease, supporting discoveries that advance human health.

Read More:KredosAi Raises $7M in Series A Funding Led by BMW i Ventures